Home › Crohn's Disease › Arizona
Crohn's Disease clinical trials in Arizona
17 studies for Crohn's Disease are looking for participants at sites in Arizona.
Cities in Arizona
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Elite Clinical Studies /ID# 280477, Phoenix
- Gi Alliance - Arizona Digestive Health - Sun City /ID# 284084, Sun City
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 5, 2026 · NCT07697456A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- GI Alliance - Sun City ( Site 5118), Sun City
- University of Arizona Clinical and Translational Sciences Research Center ( Site 5111), Tucson
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 2, 2026 · NCT06430801A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- AZ Gastro Care, Chandler
- Spectrum Research Institute LLC, Gilbert
- GI Alliance- Sun City, Sun City
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- AZ Gastro Care, Chandler
- Research Solutions of Arizona, Litchfield Park
- Mayo Clinic, Scottsdale
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Onyx Clinical Research - Site Number:8400021, Peoria
- One of a Kind Clinical Research Center AZ, LLC-Site Number: 8400061, Scottsdale
- Scottsdale Clinical Trials-Site Number: 8400145, Scottsdale
- and 1 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Phoenix Children's Hospital /ID# 255766, Phoenix
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 23, 2026 · NCT05995353A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- GI Alliance Sun City, Sun City
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Mayo Clinic Arizona, Scottsdale
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Phoenix Children's Hospital, Phoenix
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Aug 3, 2026 · NCT06100289A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Phoenix Childrens Hospital, Phoenix
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 22, 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Phoenix Children's Hospital, Phoenix
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Phoenix Childrens Hospital - Thomas Rd - PIN, Phoenix
RecruitingPhase 3
Ages 2 and older · All sexes · Updated May 7, 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Phoenix Childrens Hospital, Phoenix
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated May 5, 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Scottsdale Gastroenterology Specialists, Scottsdale
- GI Alliance -Gurnee, Sun City
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Apr 27, 2026 · NCT06456593A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400024, Tucson
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Mar 27, 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Scottsdale
- Mirador Therapeutics Selected Site, Sun City
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Mayo Clinic Arizona, Scottsdale
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Dec 10, 2025 · NCT06721962From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.